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Abstract
A phenocopy is defined as an environmentally induced phenotype of one individual which is identical to the genotype-
determined phenotype of another individual. The phenocopy phenomenon has been translated to the drug discovery
process as phenotypes produced by the treatment of biological systems with new chemical entities (NCE) may resemble
environmentally induced phenotypic modifications. Various new chemical entities exerting inhibition of the kinase activity
of Transforming Growth Factor b Receptor I (TGF-bR1) were qualified by high-throughput RNA expression profiling. This
chemical genomics approach resulted in a precise time-dependent insight to the TGF-b biology and allowed furthermore a
comprehensive analysis of each NCE’s off-target effects. The evaluation of off-target effects by the phenocopy approach
allows a more accurate and integrated view on optimized compounds, supplementing classical biological evaluation
parameters such as potency and selectivity. It has therefore the potential to become a novel method for ranking
compounds during various drug discovery phases.
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Introduction
A phenocopy is defined as an environmental induced, non-
heriditary phenotype of one individual which is identical to the
genotype-determined phenotype of another individual. In other
words, the phenocopy induced by the environmental conditions
mimics the phenotype produced by a gene. For example, a
phenocopy is observed in Himalayan rabbits which have a white
colored coat along with a black tail, nose, and ears when raised in
moderate temperatures. However, when raised in colder climates,
they develop phenotypically similar to genetically different black
coated rabbits. The Himalayan rabbits exhibit black coloration of
their coats, resembling the genetically encoded black rabbits.
Hence in colder climates the Himalayan rabbit is a phenocopy of
the black rabbit [1]. The phenocopy phenomenon can be
translated and used for drug discovery processes through
inhibiting a drug target with different functional modulation
technologies and thereby mimicking a phenotype of interest.
Inhibition can be achieved using RNA interference (RNAi), to
knockdown a target, or by small molecule inhibitors (new chemical
entities – NCEs) to block or inhibit the activity of the target. These
modulators can be used as a particular environmental condition by
treating in vitro cultured cells. Effects of the inhibition can be
monitored by high-throughput RNA expression profiling and
derived gene expression signatures represent either partial or exact
phenocopies. Therefore, phenocopies consist of gene expression
signatures caused by different pathway modulator treatments
(NCE and siRNA). Subsequent analysis of the gene expression
signatures will elucidate two critical issues for drug discovery: First,
getting a deeper insight into a target’s biology by identifying genes
whose expression is transcriptionally altered after interfering with
the target of interest, referred to as the TGF-b signature (on-target
signature). Second, single observations for each modulator used
can identify genes regulated independent of the target inhibition,
referred to as the off-target signature. The TGF-b signature is
independent on the used modulator and defines the biological
mode of action of the target. In contrast, the off-target signature
defines the mode of action for each modulator used, which has to
be not necessarily limited to the inhibition of TGF-bR1 only.
So far, microarray technology has been successfully applied
during the drug development process for target discovery by
profiling disease models [2], for target validation by profiling
alterations caused by disease-related genes [3,4], for elucidating
drug metabolism by measuring transcriptional changes of known
drug metabolizing genes in rat livers or human hepatocytes [5,6],
and to address drug safety in toxicogenomics approaches [7,8].
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between target validation and drug metabolism and aimed to
support the hit-to-lead or lead optimization processes. In fact gene
expression signatures have been used to functionally annotate and
characterize small molecules in yeast [9–11] and in mammalian
cells [12–14]. However, these approaches mainly focused on the
identification of new NCEs directed against a given target, or to
build novel connections to a disease, but not to obtain an in depth
analysis of the off-target effects. In our study we introduced several
optimized parameters to achieve a comprehensive qualification of
compounds: First, the screening platform was chosen by the use of
a relevant cellular system functionally expressing the drug target
and its downstream signaling. Second, various time points and
concentrations were monitored. Third, siRNAs against TGF-bR1
were used as an additional target modulation technology to
confirm the results obtained with the NCEs. By combining those
data, the off-target signatures were used to identify the most
selective NCE among the compounds tested and to detect
undesirable off-target effects such as impairment of the innate
immune system or of death receptor signaling. The data also allow
to identify the target promiscuity of the NCE e.g. described for the
multiple targeting of the anti-cancer drug Imatinib (Gleevec) or
the schizophrenia drug Clozaril [15]. These polypharmacological
approaches, most notably discussed in fields of cancer treatment
[16,17], cannot be faced with conventional single target-based
assays but need approaches containing multi-parallel readouts for
NCE characterization.
In this proof of concept study the phenocopy approach was
applied during the lead optimization (LO) phase of our
Transforming Growth Factor b Receptor I kinase (TGF-bR1)
research project. 5 advanced NCEs from the project [18] (BI1-
BI5, see Roth et al.) together with two competitor compounds [19]
(Ex1–Ex2) were qualified (Fig. 1). TGF-b is a multifunctional
cytokine with effects on cell growth, migration, adhesion,
differentiation and apoptosis. Thus, malfunctions within the
TGF-b signaling pathway may result in cancer, fibrosis and
diverse hereditary disorders [20–22]. While the primary focus is in
the area of cancer, there are three different therapeutic approaches
under investigation dealing with antisense oligonucleotides,
monoclonal antibodies (NBEs) and small molecular inhibitors
(NCEs) [23].
In the present study, treatment of TGF-b stimulated cells with
NCEs and siRNAs was monitored by high-throughput RNA
expression profiling. The time-dependent TGF-b–dependent
mechanism-of-action was determined and single NCE-specific
and/or lead-structure-specific off-target signatures were identified
(Fig. 2). The phenocopy assessment of the NCEs during the lead
optimization process supplemented classical biological evaluation
parameters such as potency and specificity data. It therefore allows
a more integrated view on the quality of the NCEs. Ideally it can
serve as a tool for ranking compounds classes or even single
compounds, facilitating the decision on follow-up activities such as
further vivo studies (efficacy & toxicology).
Results
Phenocopy Platform
To perform the phenocopy approach HaCaT cells (human
keratinocytes) were cultured to analyze TGF-bR1 modulators.
siRNAs and seven NCEs (Fig. 1) were used to monitor and
characterize mRNA transcriptional changes upon knockdown of
TGF-bR1 mRNA or inhibition of TGF-bR1 kinase activity.
Subsequently, the inhibition of the TGF-b–dependent signal
transduction by the selected candidates was confirmed. To cover
the entire TGF-b signaling process three readouts representing
early, intermediate, and late responses to TGF-b stimulation were
performed. Direct downstream targets of the activated TGF-bR1
kinase are Smad2 and Smad3 proteins. Their phosphorylation
initiates the intracellular signaling cascade (Fig. S1a). Therefore, as
an immediate early readout a phospho-Smad2/3 ELISA was used
to determine the cellular IC50 values for all seven NCEs.
Additionally, to cellular IC50 values the biochemical IC50 values
were obtained from kinase assays. A wide range in the inhibition of
TGF-bR1, from 19 nM (BI3) to 1537nM (Ex2), was observed. A
detailed list of potencies of all NCEs is provided in Fig. 1.
A well characterized downstream target of TGF-b signaling is
PAI-1 (SERPINE-1) [24]. The expression of PAI-1 at mRNA
levels (qRT-PCR) and at protein levels (ELISA) for TGF-b signal
transduction was measured as an intermediate and a late response.
An up to 70-fold up-regulation of PAI-1 mRNA was detected
6 hours after TGF-b stimulation (Fig. S1b). Subsequently, the
supernatants were analyzed for PAI-1 protein expression. The
expression of PAI-1 protein was delayed compared to the mRNA
expression and can therefore be considered as a late response to
TGF-b stimulation. The first significant increase was seen
12 hours post stimulation (Fig. S1c).
To guarantee optimal siRNA-mediated TGF-bR1 knockdown
10 commercially available siRNAs were qualified. First, knock-
down efficacy was determined on mRNA level. Only 5 siRNAs
(A1, D1, D2, Q3 and Q4) which led to a knockdown of more than
90% were selected for off-target profiling (Fig. S2a). Second,
inhibition of downstream signaling of each selected siRNA was
determined by phospho-Smad2/3 (Fig. S2b) and PAI-1 ELISA
(Fig. S2c). Interestingly, although transfection of siRNA D1
resulted in the best mRNA knockdown (98%), this finding was
not represented in the functional readouts. The strongest
functional knockdowns were observed for siRNA A1. Finally,
the off-target effects of all siRNAs were determined by microarray
analysis using Illumina Beadchip technology. All deregulated
genes (p-value ,0.01 and |LR| $1) were identified for the
selected five siRNAs (Fig. S3). To exclude genes from the off-target
list that are relevant for the mechanism of the procedure or
relevant for the TGF-bR1 biology, only those genes were selected
that were uniquely deregulated by the respective siRNA. Due to its
superior functional knockdown abilities (Fig. S2b) and little off-
target effects siRNA A1 (Fig. S3b) was used in all further
experiments.
The profiling of seven NCEs at seven different concentrations
and three time points, including siRNA A1, all appropriate
controls and biological triplicates for each condition resulted in an
overall experimental setup of 621 samples to be submitted to array
profiling.
TGF-b signature
To gain a deeper insight into the TGF-b biology we first
identified genes that are regulated due to TGF-b stimulation
(5 ng/ml). To unravel the time-dependent effects of TGF-b
treatment HaCaT cells were stimulated with TGF-b for 2 h, 4 h
and 12 h. While immediate early genes that are directly regulated
by the TGF-b pathway are detected at 2 h post stimulation, more
and more secondary effects linked to TGF-b signaling are found
after 4 h and/or 12 h. To avoid arbitrary log ratio cut-offs we used
a modulator-based approach to identify TGF-b dependent gene
regulation. We applied two criteria to identify TGF-b regulated
genes: First, genes that were significantly deregulated (p-value
,0.01) in a basic comparison of TGF-b stimulation versus
unstimulated cells were further analyzed. We found 1046, 1949
and 5725 genes (6525 non-redundant genes) to be regulated 2 h,
Phenocopy
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genes were proven to be affected dose-dependently by kinase
inhibitor treatment after TGF-b stimulation. The approach
allowed separating these genes from potential compound related
off-target effects. All transcripts identified for each NCE were
merged to a common signature of TGF-b dependent genes. This
strategy allowed the identification of a common on-target
signature minimized for the amount of false positive and false
negative genes. The Venn diagram (Fig. 3b) depicts the number of
genes that were identified after 2 h, 4 h, and 12 h of stimulation:
446 genes (2 h), 772 genes (4 h) and 1932 genes (12 h). All gene
identifier annotations and regulations are listed in Table S1a.
Beyond the inhibition of the kinase activity by chemical
compounds, the TGF-b pathway was also silenced by siRNA
knockdown. All previously selected genes (TGF-b stim. vs.
unstimulated cells, Fig. 2a) were tested to be regulated by
siRNA-mediated knockdown of TGF-bR1. To exclude mechan-
istical effects, genes were only selected when they were regulated
by siRNA A1, and not by a control siRNA (p-value ,0.01). By
siRNA knockdown of TGF-bR1, 303 (2 h), 419 (4 h) and 1112
(12 h) genes are identified as TGF-b dependent (Fig. 3c). Although
fewer genes were identified compared to the NCE approach, the
majority of genes were identified by both approaches. All gene
identifier annotations and regulations are listed in Table S1b.
According to the siRNA transfection procedure, a slightly different
experimental setup was performed regarding cell seeding and
culture conditions. That variation resulted in procedure-specific
changes in gene regulation, which had to be separated from the
TGF-b signature. Addressing the level of TGF-bR1 activity upon
siRNA transfection, we analyzed the expression of PAI-1 as a
surrogate marker for the TGF-b signaling activity. Using NCEs,
we were able to inhibit the PAI-1 expression by more than 95% at
all time points. In contrast, the use of siRNA A1 reduced PAI-1
levels only to 62% after 2 h of TGF-b stimulation (Fig. 3d).
Despite the high efficiency of the siRNAs (A1 showed a mRNA
knockdown efficiency of greater than 90%; Fig. S1a) analyzed at
the time points the siRNA treatment resulted only in a partial
reduction of the TGF-b signaling activity most likely due to the
long half-life of the receptor protein.
Subsequently, the genes of the TGF-b signature were used to
perform gene set enrichment analysis (GSEA) [25,26]. The
annotation of the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways delivered gene-sets corresponding to 201
different pathways [27,28]. The GSEA resulted in 16 different
Figure 2. Phenocopy workflow. In vitro cultured HaCaT cells stimulated with TGF-b were treated with NCEs inhibiting the kinase activity of TGF-
bR1 or with a siRNA specific against TGF-bR1. After 2 h, 4 h and 12 h total RNA was isolated for hybridization on Illumina Beadchips and expression
profiles were generated. The concentration and time-dependent on-target- (TGF-b signature) as well as the off-target signatures for every NCE were
obtained by bioinformatic analysis. Compounds were qualified according to their off-target signature by influencing other pathways.
doi:10.1371/journal.pone.0014272.g002
Figure 1. List of profiled TGF-bR1 kinase inhibitors. The chemical structures and characteristics of profiled compounds are listed. The potencies
(IC50) for the inhibition of TGF-bR1 kinase, Smad2/3 phosphorylation (pSmad) and PAI-1 protein are indicated for compounds BI1 to BI5 (indolinones
[INDO]) and Ex1 and Ex2 (pyridopyrimidinones [PyPy]). The PubChem CIDs are indicated. According to the chemical synthesis of the compounds
(Roth et. al), the corresponding compounds identification numbers are indicated in brackets.
doi:10.1371/journal.pone.0014272.g001
Phenocopy
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e14272Figure 3. On-target Signature. The on-target signature was generated based on gene regulations upon treatment with TGF-b, TGF-bR1-kinase
inhibitors (NCEs) or a siRNA. A: Volcano plots of the comparison between TGF-b stimulated and non stimulated cells at 2 h, 4 h & 12 h. Every circle
represent a single transcript. The x-axis shows the log2 ratio (LR) between TGF-b stimulated vs. untreated HaCaT cells. The y-axis is scaled as negative
log10 [p-value] as an indicator of significance. P-values were FDR-corrected according to Benjamini-Hochberg. Blue circled genes are significantly
regulated by the stimulation with TGF-b (p-value ,0.01). B: The list of non-redundant genes was filtered for a dose-dependent regulation upon NCE
treatment and TGF-b stimulation.: 446, 772 and 1932 genes were identified as the NCE-dependent on target TGF-b signature after 2 h, 4 h and 12 h.
C: The siRNA dependent TGF-b signature identified 307, 419 and 1112 genes which were classified as siRNA-dependent on-target TGF-b signature
genes after 2 h, 4 h and 12 h. D: Expression level of PAI-1 mRNA as a surrogate marker for TGF-b signaling pathway activity after treatment with NCE
B1 or siRNA. Treatment with NCE BI1 resulted in a complete knockdown of PAI-1 expression (.95%) for all time points. In contrast the siRNA A1
mediated knockdown of the TGF-b signaling only reduced PAI-1 levels partially to 62%, 65% and 78% after 2 h, 4 h and 12 h of TGF-b stimulation. E:
Gene set enrichment analysis (GSEA) using KEGG gene annotation resulted in 16 significantly affected genesets/signaling pathways. Clustering of -
log10[p-values] using complete linkage and manhattan distance resulted in four major clusters: immediate early affected pathways (cluster 2)
permanently affected pathways with emphases at early (cluster 1) and late time points (cluster 4) or late established events (cluster 3). The color code
defines the significance determined by Fisher’s exact test: blue ,2 – not significant; white =2 – significant & red .2 – highly significant).
doi:10.1371/journal.pone.0014272.g003
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b stimulation of HaCaT cells. The signaling pathways were
clustered in four groups (Fig. 3e). Not surprisingly, the TGF-b
signaling pathway itself as well as directly affected pathways like
WNT and p53 signaling were significantly regulated by the
treatment of TGF-b (cluster 1). In cluster 2 MAPK, cytokine,
ErbB, Shh, as well as apoptosis signaling pathways are strongly
affected immediately early upon TGF-b stimulation. The
modulation is reduced at later time points (4 h & 12 h), when
more secondary effects, such as DNA polymerase, actin cytoskel-
eton, amino acid metabolism, gap junction and tight junction
signaling become apparent (cluster 3). The activation of these
pathways in combination with the modulation of the cell cycle and
cell communication activity (cluster 4) seem to be the phenotypic
consequences to TGF-b stimulation of HaCaT cells. To proof the
findings obtained from the KEGG analysis, we additionally used
Ingenuity Pathway Analysis (Ingenuity SystemsH, www.ingenuity.
com) to link and group genes from the TGF-b signature. In line
with the KEGG results, the analysis identified the same
connections and networks containing signaling but also WNT
and Erk/MAPK signaling (Fig. S4). In addition, diverse networks
of genes were identified that play a role in embryonic development
of different organs, but also in cellular proliferation and growth
(data not shown). Having identified the TGF-b signature (on-
target signature) as well as the affected pathways by GSEA, we
next screened the seven NCEs for their specific off-target effects
and affected pathways.
Off-target signature
In our study, we define a phenocopy as copy of a phenotype
(measured by gene expressions). Gene expressions are therefore
the first step that defines the phenotype of an organism. Each
compound treatment resulted in a unique gene expression
signature of regulated genes. These signatures are composed of
the cellular response to two different stimuli (TGF-b and NCE)
and are integrated to the corresponding treatment signature. An
off-target effect is defined as observed gene expression change
induced by NCE treatment independent of the previously
determined effects following TGF-b signal inhibition. Examples
for all different types of off-targets are given in Figure S5. Thereby,
elucidating the effects based on NCE treatment is more
demanding since both TGF-b and off-target effects occur. Minor
effects can also be observed for the interaction of the vehicle
(DMSO) and the NCEs. The effects of the different stimuli overlap
and also interfere with each other impeding with a clear signature
dissection. The profile of a given gene may therefore be dependent
on which effect prevails and thus dose-dependency might no
longer be observed. In general, all regulated genes can be grouped
into six classes: Pure TGF-b effects (Fig. S5a) and pure off-target
effects (Fig. S5b), where genes are dose dependently regulated
dependent or independent of TGF-b. Additionally, an integration
of both TGF-b and off-target effects can be detected: an NCE
effect can be additive (Fig. S5c) or inverse (Fig. S5d) to the effect of
TGF-b. Furthermore, opposed bipolar effects for high and low
dosage of the NCE mostly linked with toxicity (Fig. S5e), or
common- and dose independent effects observed for all seven
NCEs can be identified (Fig. S5f).
In a first approximation the NCE treatment phenotypes
(phenocopies) were determined as the total of all regulated genes
(p-value ,0.01 and |LR| $1) comparing NCE treated and TGF-
b stimulated cells to DMSO control treated TGF-b stimulated
cells. This analysis was done separately for each of the tested
compounds at each concentration. Subsequently, the different
phenotypes obtained after 2 h NCE treatment were clustered to
unravel similarities between the different signatures (Fig. S6). The
early time point allowed focusing on primary affected genes that
were altered as direct response to the treatment. Hierarchical
clustering clearly revealed two major clusters separating the group
of indolinones (BI1 to BI5) from the pyridopyrimidinones (Ex1 &
Ex2). The fact that most obviously the specific chemotype has a
major impact on differences in gene expression confirms that the
classical notion of chemotypes determining biological profiles of
NCEs holds true in this case. However, not only the scaffold itself
but also the specific decoration of each chemotype affected gene
expression. The hierarchical cluster analysis demonstrates that
treatment signatures can be used to differentiate even between
analogs of the same chemotype.
However, the identification of a particular off-target based on
this approach is difficult. Further analyses were therefore
performed to extract the compounds’ off-target effects from
treatment signatures. As abovementioned not all off-target effects
can be identified through dose dependence correlation due to
overlapping, inverse and additive effects (Fig. S5). Hence off-
targets can only be identified based on NCE treated samples in
presence and absence of the TGF-b stimulus. All regulated genes
(p-value ,0.01 and |LR| $1) comparing compound treated cells
(either 0.08 mMo r2 mM) to DMSO treated controls were
selected. Genes were considered once the regulation is observed
during compound treatment upon TGF-b stimulation as well as
without TGF-b stimulation. Thus, we ensured to select only drug
target and stimulation-independent alterations. All genes that
match the criteria were allocated to the off-target signature of the
NCE after 2 h, 4 h and 12 h. Based on this analysis, huge
differences in the amount of off-target genes were observed. While
treatment with BI1 deregulated 2752 genes at all time points, BI3,
deregulated only 973 genes. Slightly more off-target genes were
identified for the indolinones BI2, BI4 and BI5 (1050, 1064 and
1100). Both pyridopyrimidinones regulated 1347 (Ex1) and 1306
(Ex2) genes. The largest off-target increase over time was seen for
Ex1 and Ex2 with almost four times more genes being regulated
comparing the 12 h to the 2 h time point. In contrast the amount
of off-targets for the five indolinones is at a maximum doubled
within this period (Fig. 4a). In summary, looking at the off-target
signatures in general, the indolinones appeared more favorable
compared to the pyridopyrimidinones at later points in time.
Among the indolinones, BI2 to BI5 deregulated fewer genes than
BI1 at all points in time which was paralleled by the different
kinome specificities (see Chapter ‘Kinase Profiling’). It also
confirmed the structure-activity relationships described in Roth
et al. [18] demonstrating that indolinones substituted in position 5
(such as BI1) showed a less favorable selectivity profile compared
to indolinones substituted in position 6 (such as BI2-5). Among the
indolinones, BI3 appeared to be the most attractive compound
when merely looking at the off-target analysis.
Pathway Analysis
Ingenuity Pathway Analysis was used to subsequently analyze
the off-target signatures of all NCEs in order to enrich influenced
signaling pathways. We found 39 (2 h), 38 (4 h) and 51 (12 h)
canonical signaling pathways scored with a significant –log10[p-
value] .2 (Fisher’s exact test) for at least one of the NCEs (Fig. 4b).
Pathway analysis again separated the indolinones from the
pyridopyrimidinones indicating that both series share not only a
common mode of action like TGF-b inhibition, but also generate a
distinct affection of other pathways by their specific off-target
function. In accordance with the structure-activity findings
mentioned before, BI1 stands apart from the four other
indolinones with 5 significantly ranked pathways and the smallest
Phenocopy
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pathways and almost exclusively regulates genes involved in
different cancer pathways. The indolinones BI2 and BI4 regulated
genes that are significantly enriched in only four (BI2) and two (BI4)
signaling pathways, respectively. However, pathways such as the
Aryl Hydrocarbon Receptor Signaling and the LPS/IL-1 mediated
inhibition of RXR function are also significantly ranked high for up
to six compounds indicating a more general effect like a xenobiotic
response to NCE treatment rather than a true compound specific
effect. The highest numbers of significantly influenced pathways are
found for the two pyridopyrimidinones with 29 (Ex1) and 24 (Ex2).
Additionally, genes involved in 30 out of the 51 signaling pathways
are exclusively regulated by Ex1 or Ex2 treatment.
Interestingly, 13 out of the 51 identified pathways are known
mediators of toxicity and cell death. These 13 pathways reach
highest significance scores for either Ex1 or Ex2 with eight being
solely affected by the two pyridopyrimidinones indicating a
cytotoxic mode of action for both of them. Besides cytotoxicity
these two NCEs deregulate genes involved in inflammatory
processes like IL-6 signaling, ERK/MAPK signaling, and p38
MAPK signaling (Fig. 4b).
Results from the pathway analysis strongly implied different
induced phenotypes after treatment with specific NCEs. However,
pathway analysis tools only generate hypotheses and their proof of
biological relevance must be verified. To address the accuracy of
the pathway analysis we aimed to confirm the in silico generated
hypotheses by experimental laboratory data.
Cytotoxicity and Cell Death
According to the expression data, both pyridopyrimidinones
(Ex1 & Ex2) are involved in processes such as cell death and
inflammation. To investigate several cytotoxicity parameters, we
performed high content screen analysis using the high-capacity
automated fluorescence imaging platform from Cellomics. HaCaT
cells were incubated with increasing compound concentrations
(3.2 nM – 50 mM) for 24 h. Subsequently the cells were stained
with cytotoxicity cocktails and images were acquired and analyzed
on the Cellomics ArrayScan II. Cells were stained using i) Hoechst
DNA dye to count cell density and investigate nuclear conden-
sation and fragmentation, ii) LysoTracker Red to analyze the
amount of lysosomes per cell as an early marker for cytotoxicity,
iii) Sytox Green as a membrane impermeable dye to detect loss of
membrane integrity as late event for cytotoxicity (Fig. 5a).
According to the aforementioned pathway analysis the highest
toxicity is observed by treatment with Ex1 and Ex2. Cell density is
strongly decreased to less than 10% of control. Nuclear
fragmentation, lysosomal mass per cell and membrane permeabil-
ity are increased by 100% for both pyridopyrimidinones and even
lower concentrations of Ex2 were sufficient to raise the membrane
permeability of more than 50% of the control. Treatment with the
indolinones resulted in mild toxicity effects for the treatment with
BI1, BI2 and BI3 at high concentrations and almost no toxicity for
BI4 and BI5 (Fig. 5b).
To analyze the mode of cell death, we performed Caspase-3
activation assays to distinguish between apoptosis and necrosis,
since activation of this executioner caspase is a clear marker for
apoptotic cell death. Again, HaCaT cells were treated with 2 mM
of each compound for 24 hours and subsequently Caspase-3
activation was detected using a Caspase-3 Detection Kit
(Calbiochem) and quantified by flow cytometry. Among all NCEs
tested, only treatment with Ex1 resulted in an activation of
Caspase-3 with approximately 30% positive cells (Fig. 5c). This is
in line with the results of the pathway analysis in which only the
off-target signature of Ex1 exceeded the significance threshold for
Death Receptor Signaling after 4 h (data not shown) and was
further increased after 12 h (Fig. 5b). This clearly demonstrates
that it was not only possible to predict the compound’s cytotoxicity
based on mRNA profiles but also its apoptotic mode of action.
Pathway analysis labeled the pyridopyrimidinones for cell death
induction, but also for affection of inflammatory mechanisms. To
proof this prediction, HaCaT cells treated with each compound
were analyzed for the induction of pro-inflammatory cytokines
(IL1-b, TNF-a, IL-8 and IL-6). While no significant alteration in
release of IL1-b, TNF-a, and IL-8 was observed, we could
demonstrate that IL-6 levels were dose-dependently increased after
treatment with the pyridopyrimidinones Ex1 and Ex2. Compared
to DMSO treated control cells 10 mM of Ex2 increased IL-6
secretion by factor 5 and Ex1 treatment at the same concentration
even resulted in a 25-fold increase (Fig. 5d). In summary, the
indolinones looked more favorable in this evaluation compared to
the pyridopyrimidinones.
Kinase Profiling
One pivotal issue of kinase inhibitors is cross-reactivity with
other kinases which may contribute one source of off-targets. In
vitro kinase profiling is the state of the art method to examine
selectivity of kinase inhibitors. We used the Ingenuity Pathway
Analysis database to extract the literature described downstream
targets for 239 in HaCaT cells expressed kinases. For 147 kinases
807 non-redundant downstream targets had been described and
annotated. The downstream targets were used as surrogate
markers and overlaid with the NCE’s off-target lists to assign off-
target genes to off-target kinases (Fig. S7). The correlation of the in
vitro predicted kinase inhibition with the off-targets requires some
criteria to be fulfilled: i) the kinase has to be expressed in the
cellular system, ii) the signaling pathway must be functional, which
iii) depends on the availability of appropriate ligands in the in vitro
system. As the cells in our study had been starved for compound
and/or TGF-b profiling, these criteria might have been only
partially met. Finally, iv) surrogate markers had to be described.
The regulation of surrogate markers for kinase inhibition was used
to predict the activity of upstream acting kinases for each of the
tested compounds. To proof the predictivity of our model, we
tested all compounds against 239 kinases available in the
biochemical SelectScreenTM Kinase Profiling (Invitrogen) at
concentrations of 2 mM and 200 nM. All kinases inhibited by at
least 90% at 2 mM conc. and additionally by at least 50% at
200 nM were selected as off-target kinases (Table S3). Most off-
target kinases were identified for BI1 (75) and Ex1 (60). All other
NCEs showed a higher selectivity with only 21 (BI2), 17 (BI3), 12
Figure 4. Off-target Signature. A: Every circle represents one of the seven profiled compounds. The size of each circle corresponds to the number
of off-target genes (in red). On-target genes numbers are shown in blue. B: Ingenuity pathway analysis for the off-target genes of all seven NCEs after
12 hours: Clustering of the -log10[p-values] using complete linkage and manhattan distance depicts the 51 significantly ranked canonical signaling
pathways. Off target genes deregulated by BI3 treatment affect almost exclusively 10 cancer signaling pathways (red arrows). Ex1 & Ex2 off-target
genes play a role in 12 pathways involved in cytotoxicity or cell death (grey arrows) and in five pathways involved in inflammation (green arrows). The
color code defines the significance determined by Fisher’s exact test as –log10[p-value]: blue ,2 – not significant; white =2 – significant & red .2–
highly significant.
doi:10.1371/journal.pone.0014272.g004
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PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14272(BI4), 15 (BI5) and 14 (Ex2) kinases inhibited by the respective
compound (Fig. 6b). For BI1, 84 (22.9%) of the 366 known
surrogate marker genes were found to be regulated. A comparably
good ratio was also identified for the two pyridopyrimidinones
with 84 (23.2%) out of 361 (Ex1) and 55 (24.7%) out of 223 (Ex2).
A summary of data is shown in Figure 6a and 6b. Integrating all
criteria, the identification of kinase selectivities was limited, as
shown for BI2 in figure S7. Although various annotated surrogate
marker genes were identified as off-targets, a clear association to a
specifically upstream-acting kinase was often not possible since too
many surrogate markers have been redundantly identified to act
downstream of several receptor kinases (Fig. S7). The cellular
system might be optimized in regard to the addition of receptor
ligands, but it will not replace testing NCEs in biochemical assays
for kinase selectivity.
Discussion
Since the approval of Imatinib (Gleevec) in 2001, the first
marketed kinase inhibitor, many additional kinase inhibitors have
been advanced into clinical development. The most advanced
kinase programs in research and development are aimed at the
treatment of various cancers. However, additional therapeutic
applications like immunological, metabolic-, or infectious diseases
and also the treatment of central nervous system disorders by
kinase inhibitors are under investigation [29–31]. During the
optimization of kinase inhibitors one often has to cope with
challenges like the improvement of kinase selectivity [30,32]. In
combination with the overall high attrition rates of new drug
candidates [33] there is a need for new strategies that support and
optimize the drug discovery process.
So far, the in vitro biological evaluation of NCEs was often
based on biochemical and cellular potencies, as well as on the
selectivity of the respective NCE. This limited view may result in
wrong decisions for further time and cost consuming processes,
such as in vivo experiments. In the present study, we have
established a workflow to alleviate the lead identification and
optimization of NCEs in general and kinase inhibitors in particular
by elucidating the mechanism of action of both the target and the
NCE. Thereby, more knowledge about drug candidates is
obtained at an early stage of drug discovery and several new
categories for their qualification are available (Fig. 7).
By evaluating of TGF-bR1 inhibitors, we were able to clearly
differentiate the indolinone chemotype from the pyridopyrimidi-
nones in several parameters. Furthermore, even within the
indolinone cluster differences between compounds with different
decorations were identified. Besides the detection of off-targets and
biomarkers, this strategy can also help to interpret the identified
off-target effects and offers the possibility to assign the regulated
genes to relevant biological processes and networks. This can be
handled in a flexible format by the respective scientist by defining
context relevant processes or just by prioritizing the compounds in
terms of the absolute number of affected processes or pathways. In
terms of TGF-b inhibition for instance one goal is to reduce
inflammation processes triggered by this cytokine [34]. Thus, the
predicted and confirmed pro-inflammatory properties of both
pyridopyrimidinones (Fig. 4b & Fig. 5d) are the opposite of the
desired effect making both NCEs inferior to the indolinones for the
treatment of fibrotic diseases and/or cancer. Furthermore relevant
and unwanted processes are regulation of growth and proliferation
and obviously induction of cell death (Fig. 5b). Finally, the
combination of TGF-b and off-target signatures revealed that
some compounds regulate genes inverse to the desired therapeutic
effect (Fig. S5d). This can potentially affect the efficacy of the
treatment with this NCE. Particularly both pyridopyrimidinones
regulated 217 (Ex1) and 317 (Ex2) TGF-b dependent genes in the
opposite direction to the desirable treatment effect. In contrast the
indolinones only affected a lower number (BI3: 42; BI2: 57, BI1:
70; BI5: 81; BI4: 101) of these genes.
According to the ten introduced phenocopy criteria, a couple of
compounds revealed liabilities through down-stream inhibition of
PAI-1 transcription (BI1, BI5 & Ex2), at the regulation of off-target
genes per se (BI1, Ex1 & Ex2), at the affection of inverse TGF-b
signaling (Ex1 & Ex2), at the induction of cell death (Ex1 & Ex2),
at acting as pro-inflammatory stimuli (Ex1 & Ex2) and as
promoting cellular growth and induction of cancer pathways
(BI3 & BI5) (Fig. 7). An integration of all obtained information
recommends the use of BI4 and BI2 for further optimization due
to superior overall performance of these two drug candidates.
Furthermore, our data strongly indicates that off-target effects
do not only derive from additionally inhibited kinases in line with
the fact that within the human genome over 2000 other
nucleotide-dependent enzymes can be found [35] which poten-
tially may be affected by NCEs blocking an ATP binding site. In
addition, identification of bioactive compounds revealed a high
degree of promiscuity for kinases inhibitors with GPCRs and
phosphodiesterases [36]. Hence an approach using the phenocopy
strategy will deliver a wider view on the NCEs’ selectivity. Such a
strategy will also help to accumulate an iterative knowledge about
both the drug candidates itself and the structural classes. The drug
candidates’ off-target signature can be overlaid with other
databases containing drug-dependent gene signatures like the
Connectivity Map [13]. Integration of additional data sources will
further characterize the NCEs by flagging them for potential side
effects and the identification of desirable pharmacology profiles or
even find a repositioning idea for another indication.
Not only off-target signatures but also on-target signatures can
help to support the drug discovery process. On the one hand, these
signatures can be overlaid with known disease signatures in order
to annotate the targets contribution to the state of disease. On the
other hand, it can be used to identify potent biomarkers for
Figure 5. Wet laboratory validation of in silico results. Functional assays were used to validate the predictions derived from the pathway
analysis. Cellomics high content screens analyzing cytotoxic parameters and Caspase 3 activation assays were performed to test for cytotoxicity and
cell death. IL-6 secretion was analyzed as surrogate marker for pro-inflammatory processes. A: High content screen images of HaCaT cells treated with
increasing concentrations (3.2 nM – 50 mM) of Ex1 and BI5 including DMSO (negative control) or 100 mM Valinomycin and 10 mM Chloroquine
(positive control) for 24 h. Subsequent staining with Hoechst dye, Sytox Green and Lysotracker Red determined cell density, nuclear fragmentation,
permeability and lysosomal mass per cell illustrated a strong decrease of cell density and an increase of nuclear fragmentation and lysosomal mass for
Ex1 but not for BI5 treated cells. B: Results of concentration response experiments for all seven NCEs for cell density (black) nuclear fragmentation
(grey), permeability (blue) and lysosomal mass (red) obtained from Cellomics high content screen analysis. Values of NCE treated cells are compared
to DMSO treated cells and shown as percent of control (POC). Outlier data point are shown as filled red circles C: HaCaT cells were treated with 2 mM
of each NCE and incubated for 24 h. Caspase-3 activation was analyzed. A significant signal was identified only after treatment with Ex1 (30%) or with
Valinomycin (15%) and Chloroquine (100%). D: HaCaT cells were treated with increasing NCE concentrations and DMSO for 12 h. IL-6 levels were app.
25-fold increased after Ex1 treatment and 5-fold increased after Ex2 treatment compared to DMSO treated cells. Student t-test was used to calculate
the significance compared to DMSO treated cells (*,0.01 & **,0.001). All error bars indicate the standard deviation of n=3.
doi:10.1371/journal.pone.0014272.g005
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assay development process. This is especially important if the
target’s biology is not as well characterized as for TGF-bR1.
However, using the phenocopy strategy we were able to
significantly increase the amount of known TGF-b regulated
genes by several hundred compared to earlier studies [37–41].
Neither the complexity of a living organism nor a disease state
can be entirely represented by profiling of a single cell line.
Nevertheless, the phenocopy strategy demonstrates one possibility
to significantly alleviate the drug discovery process at an early
stage. Comparing such an approach to classical toxicology testing
or toxicogenomics studies, the phenocopy strategy offers a couple
of advantages: it addresses on- and off-target effects and is able to
differentiate between target-related vs. compound-related events.
This differentiation is only possible when a couple of compounds
of different compound classes will be investigated. Due to costs and
capacities, the analysis of a certain number of compounds can only
be run in vitro. Although cellular systems cannot replace in vivo
studies, they show less variability, guarantee the expression and
signaling of the target protein and are less cost and time
consuming.
The phenocopy approach offers an opportunity to qualify and
rank compound classes and single compounds early during hit-to-
lead and lead optimization processes, which will subsequently
reduce the attrition rates later on, e.g. during toxicological
assessment of the development candidates. However, the addition
of new technologies and checkpoints like phenocopy is contribut-
ing to the ever-rising costs of getting innovative medicine to the
Figure 6. Kinase Selectivity. A: Each compound was profiled against a panel of 239 protein kinases and the number of kinases inhibited by each
compound is shown (Table S3). No surrogate marker (e.g. literature known downstream target of a given kinase) were identified for 92 enzymes,
whereas 807 surrogate markers were identified for 147 of the enzymes. Based on the kinases inhibition profile of each compound, the expression of
these kinase in HaCaT cells and the availability of surrogate markers the number of potentially effected surrogate marker genes was predicted. B:
Kinome dendrograms used for visualization were shown with permission from Cell Signaling Technology, Inc. (http://www.cellsignal.com). Human
kinome dendrograms showing the NCEs’ kinase specificity profiles. Circle size corresponds to the percentages of inhibition of the kinase at 200 nM
concentration. AGC – Containing PKA, PKG, PKC families; CAMK – Calcium/calmodulin-dependent protein kinase; CK1 – Casein kinase 1; CMGC –
Containing CDK, MAPK, GSK3, CLK families; STE – Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK – Tyrosine kinase; TKL – Tyrosine kinase-
like.
doi:10.1371/journal.pone.0014272.g006
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used tools during early lead generation processes will become
crucial for the discovery of novel quality of entities in a changing
pharmaceutical industry. One useful tool is the phenocopy
principle, where external stimuli like the climate of the
environment for the Himalayan Rabbit or like NCEs, siRNAs,
antibodies or aptameres for the inhibition of a cellular process is
committing a certain phenotype. By investing in qualification of
NCEs during the early drug discovery process, later on the
attrition rate during development phases will be reduced.
Indirectly, this investment will reduce the overall cost for
developing innovative medicine.
Methods
Cell culture, NCE treatment and siRNA transfection
HaCaT cells were cultured under standard conditions [42].
Cells were seeded in 96-well (ELISA) or in 24-well (RNA
expression profiling) plates and grown overnight to a confluence
of approximately 70%. Cells were starved for 3 h in DMEM
containing no FCS. Cells were pre-incubated with increasing NCE
concentrations (0.0032, 0.016, 0.08, 0.4, 2, 10, 50 mM) for 15 min
and subsequently stimulated with 5 ng/ml of TGF-b1 (R&D
Systems) and incubated for the indicated time points.
10 TGFbR1-specific siRNAs were purchased from Ambion,
Dharmacon or Qiagen and a nonsense control siRNA was
purchased from Dharmacon. All siRNAs were prepared according
to manufacturer’s instructions. For transfection experiments cells
were seeded in 24-well plates and grown overnight to a confluency
of 50–70%. siRNAs were transfected at a final medium
concentration of 20 nM. Cells were transfected using Dharma-
con’s DharmaFECT1 reagent. 24 h post transfection, the medium
was replaced. 48 h after transfection cells were washed with PBS
and lysed using RLT buffer (Qiagen).
RNA extraction
RNA isolation was carried out using a MagMAX
TM Express-96
Magnetic Particle Processor (Ambio) and the MagMAX
TM-96
Total RNA Isolation Kit (Ambio) according to the manufacturer’s
protocol. Total RNA concentration was quantified by fluorescence
measurement using SYBR Green II (Invitrogen) and a Synergy
HT reader (BioTek) as previously described [43]. The RNA
quality was characterized by the quotient of the 28S to 18S
ribosomal RNA electropherogram peak using an Agilent 2100
bioanalyzer and the RNA Nano Chip (Agilent).
Amplification, labeling and Beadchip hybridization of
RNA samples
Illumina TotalPrep RNA Amplification Kit (Ambion) was used
to transcribe 200 ng toRNA according to the manufacture’s
recommendation. A total of 700 ng of cRNA was hybridized at
58uC for 16 h to the Illumina HumanHT-12 Expression
Beadchips (Illumina). Beadchips were scanned using an Illumina
BeadArray Reader and the Bead Scan Software (Illumina).
Data processing
Data has been processed with BeadStudio version 3.0 and the R
Language and Environment for Statistical Computing (R) 2.7.0
[44,45] in combination with Bioconductor 2.2. [46]. The
Bioconductor lumi package [47] has been used for quality control
and normalization. The data has been log2 transformed and
normalized using robust spline normalization (rsn). Linear models
(Bioconductor package limma) [48] were used to calculate log2
ratios, the resulting p-values were FDR-corrected [49]. The raw
data of 640 Illumina beadchips are accessible as MAIME-
compliant entry at Array Express (E-MTAB-265). A fully detailed
description of the normalization methods was recently published
by Schmid et al [50].
TGF-b signature
To define genes deregulated by TGF-b signaling, three
sequential filtering steps were applied for each time point
separately: 1) significant difference between TGF-b stimulated
and unstimulated cells, 2) significant deregulation by at least one
compound concentration, 3) dose dependent deregulation (R
package IsoGene [51]). For each time point the probes that passed
all three filters are pooled to the final TGF-b signature.
Figure 7. NCE ranking. Quality parameters used to gauge the seven NCEs. The phenocopy strategy introduces ten additional parameters dealing
with potency, off-target numbers and affected pathways. NCEs are ranked from blue (good) to red (bad). Integration of all parameter scores identifies
BI4 and BI2 as superior to all other NCEs.
doi:10.1371/journal.pone.0014272.g007
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To detect transcripts that are deregulated due to off-target effects
of the compounds unstimulated cells (wotgf class) as well as TGF-b
stimulated cells (tgf class) were considered for compound
concentrations 0.08 and 2 mM and the respective controls.
Transcripts that are up/down regulated by either compound
treatment (wotgfup/wotgfdown) or by TGF-b stimulation together
with compound treatment (tgfup/ tgfdown) were detected based on
all pair wise comparisons. The off-target signature is
composed of transcripts for which (tgfup
‘ wotgfup) ~
(tgfdown
‘ wotgfdown) ~ (tgfup
‘ wotgfdown) ~ (tgfdown
‘
wotgfup). For a more detailed explanation, see Methods
S1. All off-target genes are listed as supplemental data in Table S2.
Ingenuity Pathway Analysis (IPA) and Gene Set
Enrichment Analysis (GSEA)
Based on the on- and off-target signatures, standard IPAs were
used to generate networks and perform GSEA using Fisher’s exact
test for canonical pathways defined by the Ingenuity Knowledge
Base.
Additionally, GSEA for the on-target signatures was conducted
using Fisher’s exact test based on gene sets defined by KEGG
pathways as annotated by the Bioconductor package KEGG.db
version 2.2.0.
The p-values calculated based on Fisher’s exact test were
clustered using manhattan distance and complete linkage.
High content screen Cellomics
The high-content cytotoxicity assay 1 was performed according
to the manufacturer’s instructions (ThermoFisher Cellomics).
Briefly, HaCaT cells were cultured overnight in black 96-well
plates, incubated for 24h with each NCE at the indicated
concentrations and stained with cytotoxicity cocktail. Cells were
fixed, washed and scanned on the Cellomics ArrayScan II
platform. Images were analyzed with the Cell Health image
analysis algorithm. Cytotoxicity indices were calculated for each of
the four parameters to indicate the percentage of cells outside of
the normal range which was defined using a vehicle-treated
reference cell population.
Caspase-3 Assay
Cells were seeded in 6-well plates and grown overnight to a
confluence of approximately 70% before they were treated with
2 mM of each NCE and incubated for 24 hours. Caspase-3 activity
was quantified using Facs Canto (BD Biosciences) and the
Caspase-3 Detection Kit (Calbiochem) according to the manufac-
turer’s instruction.
ELISA analysis of IL1-b, TNF-a, IL-8 and IL-6
To analyze the expression of these four cytokines cells were
treated with NCEs at the indicated concentrations and incubated
at 37uC for 12 h. Supernatants were analyzed using a Mesoscale
Discovery muliplex ELISA System (MSD) for detection according
to the manufacturer’s instruction.
In vitro kinase profiling
The SelectScreenTM kinase Profiling Service was performed
(Invitrogen) to indentify the compound selectivity against 239
kinases. Single-point kinase inhibitory activities of each compound
at 2 mM and 0.2 mM were measured at 100 mM or Km ATP
concentration. Downstream targets of the identified off-target
kinases were manually extracted from Ingenuity’s Knowledge Base
and overlaid with the NCE off-targets for comparisons.
Supporting Information
Figure S1 Phenocopy platform. Three readouts representing
early (Smad2/3 phosphorylation), intermediate (PAI-1 mRNA)
and late (PAI-1 protein) responses to TGF-b stimulation were
performed. a: phospho-Smad2/3 ELISA. This assay showed a
significant increase of Smad2/3 phosphorylation 15 minutes after
stimulation with TGF-b. Phosphorylation is further enhanced after
30 and 60 minutes and remains stable for further 60 minutes. b:
PAI-1 mRNA. Elevated PAI-1 expression was demonstrated by
qRT-PCR after TGF-b stimulation in a dose- and time-dependent
manner. c: PAI-protein. The supernatants were analyzed with a
PAI-1 ELISA for protein expression. The first significant increase
was observed 12 hours post stimulation. Subsequently, PAI-1
further accumulated in a concentration-dependent manner. All
results are representative of three independent experiments.
Student t-test was used to calculate the significance compared to
unstimulated cells (*, 0.01 & **,0.001). All error bars indicate
the standard deviation of n=3.
Found at: doi:10.1371/journal.pone.0014272.s001 (0.08 MB
PDF)
Figure S2 siRNA validation and qualification. A: siRNA knock-
down efficiency was measured by Taqman RT-PCR 48h post
transfection. 10 different commercially available siRNAs (A -
Ambion, D - Dharmacon & Q - Qiagen) were used. B and C:
siRNAs with the best knockdown efficacy (A1, D1, D2, Q3 & Q4),
as well as the untreated control (UT) were analyzed for functional
blockade of TGF-b signaling determined by inhibition of p-
Smad2/3 (b, p-Smad2/3 ELISA) or PAI-1 protein (c: PAI-1
ELISA). All error bars indicate the standard deviation of n=3.
Found at: doi:10.1371/journal.pone.0014272.s002 (0.08 MB
PDF)
Figure S3 siRNA off-target effects. Volcano plots for siRNAs
A1, D1, D2, Q3 & Q4. Total RNAs of biological triplicates were
isolated post siRNA transfection and were hybridized to Illumina
Beadchips. The off-target effects were analyzed by volcano plots.
Each circle represents a single gene of the human genome. The x-
axis depicts the log2 ratio (LR) between each siRNA and untreated
cells. The y-axis is scaled as -log10[p-value] (Student t-test) as a
indicator of significance. An off-target is defined to have a
|LR|$1 and a -log10 [p-value] . 2. a: CTRL siRNA vs.
untreated CTRL revealed no off-target effects. The siRNAs A1
revealed 22 genes to be deregulated (b), the siRNA D1 - 8 genes
(c), the siRNA D2 - 25 genes (d), the siRNA Q3 - 58 genes (e) & the
siRNA Q4 - 42 genes (f).
Found at: doi:10.1371/journal.pone.0014272.s003 (1.20 MB
PDF)
Figure S4 Ingenuity on-target Analysis. Networks of interacting
and regulated molecules from the on-target signature as generated
by Ingenuity Pathway Analysis. Molecules are represented as
nodes and the biological relationship between two nodes is
represented as an edge (line). All edges are supported by at least 1
literature reference. The intensity of the node color indicates the
degree of up- (red) or down- (green) regulation. Nodes are
displayed using various shapes that represent the functional class of
the gene product. a: A network of molecules directly related to the
canonical TGF- b signaling pathway containing genes involved in
cell signaling, connective tissue development and function and in
skeletal tissue development and function. b: A network of
molecules of the WNT and the Erk/MAPK signaling pathways
containing genes responsible for organ-, tissue and cellulare
development.
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Figure S5 Case profile definition. NCE treatment and TGF-b
stimulation resulted in six different cases profiles of gene
regulation: representative examples for on-target effects triggered
by TGF-b (a); Off-target effects triggered by a NCE (b); Integrated
effects for on and off-targets in an additive (c), inverse (d) and
bipolar (e) manner; common off-target effects induced by all 7
NCEs in a dose-independent manner (f).
Found at: doi:10.1371/journal.pone.0014272.s005 (0.12 MB
PDF)
Figure S6 Hierarchical Clustering. Hierarchical clustering of
4314 significant deregulated genes (|LR| $ 1 & p-value , 0.01)
after NCE treatment and TGF-b stimulation for 2h in HaCaT
cells. The expression patterns of the different NCE treated cells
reveal several intersections in gene regulation. The five indoli-
nones (BI1-BI5) are grouped and separated from the pyridopyr-
imidinones (Ex1 & Ex2). Expression patterns are grouped in high
vs. low dose fractions. The indolinone BI1 separates from the
other class members, which can be further divided into two
subgroups containing BI2 and BI3 and BI4 and BI5, respectively.
Blue indicates decreased expression relative to untreated cells, red
indicates increased expression.
Found at: doi:10.1371/journal.pone.0014272.s006 (1.50 MB
PDF)
Figure S7 In silico prediction of kinase hits. Projections of BI2-
specifically regulated kinase surrogate marker genes. Indicated are
all 21 inhibited kinases: 3 kinases with no affection of known
surrogate marker genes (c’), 4 kinases of which no surrogate
markers are described (c’) and 14 kinases with de-regulated
surrogate markers genes (blue line = transcriptional down-
regulation, red line = transcriptional up-regulation, red box =
in silico predicted and biochemically confirmed BI2-specific kinase
hits).
Found at: doi:10.1371/journal.pone.0014272.s007 (0.43 MB
PDF)
Table S1 TGF-b Signature. Listed are genes significantly
regulated upon TGF-b stimulation: (a) NCE treatment, (b) siRNA
treatment.
Found at: doi:10.1371/journal.pone.0014272.s008 (1.02 MB
XLS)
Table S2 Off-target Signatures. NCE dependent Off-target
Signatures identified upon 2h, 4h and 12h stimulation
Found at: doi:10.1371/journal.pone.0014272.s009 (2.33 MB
XLS)
Table S3 Each compound was profiled against a panel of 239
kinases. The kinases inhibited by each compound at 2mM and 200
nM are listed.
Found at: doi:10.1371/journal.pone.0014272.s010 (0.07 MB
PDF)
Methods S1
Found at: doi:10.1371/journal.pone.0014272.s011 (0.08 MB
DOC)
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